New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, eval...

Full description

Saved in:
Bibliographic Details
Published in:Revista española de quimioterapia 2022-04, Vol.35 Suppl 1 (Suppl1), p.46-49
Main Authors: Girón, R M, Ibáñez, A, Gómez-Punter, R M, Alarcón, T
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Azabicyclo Compounds - therapeutic use
Cilastatin - therapeutic use
Clinical Trials, Phase III as Topic
Drug Therapy, Combination - adverse effects
Humans
Imipenem - therapeutic use
New Antimicrobial Alternatives in the Treatment of Pneumonia
Patient Acuity
Pneumonia, Ventilator-Associated - drug therapy
Randomized Controlled Trials as Topic
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs. piperacillin-tazobactam (PIP/TAZ) for treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), demonstrated non-inferiority at all-cause mortality at 28 days (15.9% vs 21.3%), favorable clinical response at 7-14 days end of treatment (61% vs 59.8%) and with minor serious adverse effects (26.7% vs 32%). IMI/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min.
ISSN:0214-3429
1988-9518
DOI:10.37201/req/s01.11.2022